6-[[4-(3-Furanyl)phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-3-quinolinecarboxamide | 801312-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-[[4-(3-Furanyl)phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-3-quinolinecarboxamide
• 英文别名: 6-[4-(furan-3-yl)phenyl]sulfonyl-4-(3-methoxyanilino)quinoline-3-carboxamide
• CAS: 801312-18-5
• 化学式: C₂₇H₂₁N₃O₅S
• 分子量: 499.547
• InChiKey: XGDCETVOXKPROH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  、 3-呋喃硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 生成 6-[[4-(3-Furanyl)phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-3-quinolinecarboxamide
  参考文献：
  名称：

  Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration

  摘要：

  Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable pro. le for inhaled dosing. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.012

文献信息

• Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration
  作者：Michael D. Woodrow、Stuart P. Ballantine、Michael D. Barker、Beth J. Clarke、John Dawson、Tony W. Dean、Christopher J. Delves、Brian Evans、Sharon L. Gough、Steven B. Guntrip、Stuart Holman、Duncan S. Holmes、Michael Kranz、Mika K. Lindvaal、Fiona S. Lucas、Margarete Neu、Lisa E. Ranshaw、Yemisi E. Solanke、Don O. Somers、Peter Ward、Joanne O. Wiseman

  DOI：10.1016/j.bmcl.2009.04.012

  日期：2009.9

  Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable pro. le for inhaled dosing. (C) 2009 Elsevier Ltd. All rights reserved.